Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Health Communication and Emerging Concerns

The legacy of general health and science communication has long served as a bridge between complex biomedical developments and public understanding. Within this tradition, discussions of anti-aging and bone health have been prominent, reflecting a broad interest in maintaining physiological resilience over time. This heritage provides a foundation for examining how therapeutic interventions, initially developed to address common age-related conditions, may carry unintended consequences that warrant careful scrutiny. In the context of mass production and widespread pharmaceutical distribution, the transition from general health education to specific exposure concerns becomes particularly relevant. The same informational frameworks that once explained the benefits of bone density management now must accommodate emerging questions about long-term safety profiles. This shift requires a neutral examination of how routine clinical exposures—such as those involving bisphosphonate therapies—intersect with rare but serious adverse outcomes. The pivot toward occupational exposure concern is grounded in the principle that any widely administered agent demands rigorous post-market surveillance. When a medication like Fosamax becomes a standard component of preventive care, the potential for uncommon complications, including osteonecrosis of the jaw, necessitates transparent communication. This transition respects the legacy of health education while acknowledging that mass production amplifies both benefits and risks, demanding a balanced, evidence-informed dialogue.

Bridging General Health Education to Specific Drug Risks

Building on the tradition of health education, we now focus on the specific risks associated with Fosamax (alendronate), a bisphosphonate medication approved for osteoporosis and Paget's disease. While Fosamax effectively reduces fracture risk by inhibiting bone resorption, it has been linked to osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with the condition often occurring spontaneously or in association with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology of ONJ in the context of bisphosphonate use is not fully understood, but current multiscale characterization of jawbone provides information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Mechanistically, bisphosphonates like Fosamax suppress bone turnover by inhibiting osteoclast activity, which may impair the jawbone's ability to repair microdamage and respond to local infections or trauma, leading to necrosis.

Evidence Linking Fosamax to Osteonecrosis of the Jaw

The causal link between Fosamax and ONJ is supported by clinical reports and labeling information. The prescribing information for Fosamax states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' This section notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use or when to discontinue for dental procedures, noting only that the optimal duration of use has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Clinical Management

For affected patients, causation considerations involve assessing the timeline between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adverse reaction profile for Fosamax, including once-weekly dosing, shows similar safety and tolerability to daily dosing, with no specific mention of ONJ incidence in the adverse reactions table (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, while Fosamax is effective for osteoporosis and Paget's disease, it carries a known risk of osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures or cancer therapy. The labeling provides warnings and risk factors, but the optimal management of this risk, including the timing of drug discontinuation before dental procedures, remains an area of clinical judgment. Patients experiencing jaw symptoms while on Fosamax should be evaluated promptly, and discontinuation may be considered based on individual risk-benefit assessment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a condition where bone in the jaw fails to heal after minor trauma like tooth extraction. The prescribing information for Fosamax states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk is higher with longer duration of use and in patients with additional risk factors such as cancer, chemotherapy, or poor oral hygiene.

How common is osteonecrosis of the jaw in Fosamax users?

Osteonecrosis of the jaw is considered a rare adverse event associated with bisphosphonate use. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms suggestive of ONJ were similar in the Fosamax and placebo groups, indicating that the incidence is low (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the exact incidence is not well-defined due to the rarity of the condition.

What should I do if I develop jaw pain while taking Fosamax?

If you experience jaw pain, swelling, or non-healing sores in your mouth while taking Fosamax, you should consult your healthcare provider promptly. They may recommend a dental evaluation and consider discontinuing Fosamax based on your individual risk-benefit assessment. The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.